

Resource Summary Report

Generated by [dkNET](#) on Aug 31, 2026

CTLL-2

RRID:CVCL_0227

Type: Cell Line

Proper Citation

ECACC Cat# 93042610, RRID:CVCL_0227

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0227

Proper Citation: ECACC Cat# 93042610, RRID:CVCL_0227

Description: Cell line CTLL-2 is a Transformed cell line with a species of origin Mus musculus (Mouse)

Defining Citation: [PMID:145543](#), [PMID:9619491](#), [PMID:9744750](#), [PMID:31220119](#)

Comments: Characteristics: IL2 dependent., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Category: Transformed cell line

Organism: Mus musculus (Mouse)

Name: CTLL-2

Synonyms: CTLL 2, CTLL2, CTLL(2)

Cross References: BTO:BTO_0001482, CLO:CLO_0002636, CLO:CLO_0050181, EFO:EFO_0002821, MCCL:MCC:0000115, CLDB:cl925, CLDB:cl4995, ATCC:TIB-214, BCRC:60376, BCRJ:0281, BioSample:SAMN11397659, CCRID:1102MOU-NIFDC00051, CCRID:3101MOUGNM4, CLS:400482, DSMZ:ACC-27, DSMZCellDive:ACC-27, ECACC:93042610, ICLC:AL00003, Lonza:1012, NCBI_Iran:C538, RCB:RCB0637, Wikidata:Q54814742

ID: CVCL_0227

Vendor: ECACC

Catalog Number: 93042610

Record Creation Time: 20220427T215526+0000

Ratings and Alerts

No rating or validation information has been found for CTLL-2.

Warning: Discontinued: DSMZ; ACC-27

Characteristics: IL2 dependent., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981). **Warning:** Discontinued: BCRJ; 0281

Characteristics: IL2 dependent., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 115 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhong Z, et al. (2026) Engineered T cell membrane coated nanoparticles reverse thermo-resistance and reprogram tumor microenvironment to synergistically potentiate bladder cancer photothermal immunotherapy. Journal of nanobiotechnology, 24(1).

Zhang L, et al. (2026) ZBTB7B inhibits glioma tumorigenicity by upregulating GPR17 and CXCL10. Journal of molecular cell biology, 17(11).

Tsuruta A, et al. (2026) C-X-C chemokine receptor CXCR4 mediates diurnal changes in the aggregation and dispersion of CD8+ T cells within the tumor microenvironment. International journal of cancer, 158(6), 1740.

Cole EB, et al. (2026) IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR T cells enriched in long-lived T memory stem cells. Science advances, 12(11), eaec2632.

Rotta G, et al. (2025) Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein. Journal for immunotherapy of cancer, 13(5).

Wu J, et al. (2024) A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R γ strengthens T cell-mediated anti-tumor therapies. Cell reports. Medicine, 5(10), 101747.

Stinson JA, et al. (2024) Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(18), 4029.

Srivastava N, et al. (2024) CXCL16-dependent scavenging of oxidized lipids by islet macrophages promotes differentiation of pathogenic CD8⁺ T cells in diabetic autoimmunity. *Immunity*, 57(7), 1629.

Zhu X, et al. (2023) A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice. *Frontiers in immunology*, 14, 1114802.

Gao Y, et al. (2023) Implication of 99mTc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells. *Journal for immunotherapy of cancer*, 11(3).

Han NR, et al. (2023) The Mixture of Natural Products SH003 Exerts Anti-Melanoma Effects through the Modulation of PD-L1 in B16F10 Cells. *Nutrients*, 15(12).

Tumas S, et al. (2023) Engineered E. coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy. *Scientific reports*, 13(1), 12506.

Stinson JA, et al. (2023) Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(11), 2110.

Cammann C, et al. (2023) Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 168, 115635.

Zhao X, et al. (2022) Irradiation combined with PD-L1^{-/-} and autophagy inhibition enhances the antitumor effect of lung cancer via cGAS-STING-mediated T cell activation. *iScience*, 25(8), 104690.

Kremer J, et al. (2022) Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors. *Frontiers in immunology*, 13, 1005582.

Guo M, et al. (2022) Depletion and Reversal of Hepatocellular Carcinoma Inducing CTL through ER Stress-Dependent PERK-CHOP Signaling Pathway. *Canadian journal of gastroenterology & hepatology*, 2022, 6413783.

Meghnem D, et al. (2022) Selective Targeting of IL-15R α Is Sufficient to Reduce Inflammation. *Frontiers in immunology*, 13, 886213.

Girdhar K, et al. (2022) A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes. *Proceedings of the National Academy of Sciences of the United States of America*, 119(31), e2120028119.

Momin N, et al. (2022) Maximizing response to intratumoral immunotherapy in mice by tuning local retention. *Nature communications*, 13(1), 109.